Cinacalcet | CAS#226256-56-0 | calcimimetic

MedKoo Cat#: 315239 | Name: Cinacalcet

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. Cinacalcet is used to treat secondary hyperparathyroidism (elevated parathyroid hormone levels), a consequence of having end-stage renal disease. Cinacalcet is also indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Chemical Structure

Cinacalcet

CAS#226256-56-0 (free base)

Theoretical Analysis

MedKoo Cat#: 315239

Name: Cinacalcet

CAS#: 226256-56-0 (free base)

Chemical Formula: C22H22F3N

Exact Mass: 357.1704

Molecular Weight: 357.41

Elemental Analysis: C, 73.93; H, 6.20; F, 15.95; N, 3.92

Price and Availability

Size	Price	Availability
10mg	USD 90.00	Ready to ship
25mg	USD 150.00	Ready to ship
50mg	USD 225.00	Ready to ship
100mg	USD 350.00	Ready to ship
200mg	USD 550.00	Ready to ship
500mg	USD 950.00	Ready to ship
1g	USD 1,450.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

364782-34-3 (HCl) 226256-56-0 (free base)

Synonym

Sensipar. (R)N1(1naphthyl)ethyl33(trifluoromethyl)phenylpropan1amine, AMG073; AMG-073; AMG 073

IUPAC/Chemical Name

(R)-N-(1-(naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine.

InChi Key

VDHAWDNDOKGFTD-MRXNPFEDSA-N

InChi Code

InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1

SMILES Code

FC(C1=CC(CCCN[C@@H](C2=C3C=CC=CC3=CC=C2)C)=CC=C1)(F)F

Appearance

Liquid

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO.

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 357.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Komaba H, Hamano T, Fujii N, Moriwaki K, Wada A, Masakane I, Nitta K, Fukagawa M. Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis. J Clin Endocrinol Metab. 2022 Jun 16;107(7):2016-2025. doi: 10.1210/clinem/dgac142. PMID: 35277957. 2: Warady BA, Ng E, Bloss L, Mo M, Schaefer F, Bacchetta J. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis. Pediatr Nephrol. 2020 Sep;35(9):1679-1697. doi: 10.1007/s00467-020-04516-4. Epub 2020 May 4. PMID: 32367309; PMCID: PMC7385021. 3: Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468. PMID: 28097356. 4: Chandran M, Bilezikian JP, Lau J, Rajeev R, Yang SP, Samuel M, Parameswaran R. The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies. Rev Endocr Metab Disord. 2022 Jun;23(3):485-501. doi: 10.1007/s11154-021-09694-6. Epub 2022 Jan 18. PMID: 35041148. 5: Iqbal J, Zaidi M, Schneider AE. Cinacalcet hydrochloride (Amgen). IDrugs. 2003 Jun;6(6):587-92. PMID: 12811682. 6: Mostafa GAE, Al-Badr AA. Cinacalcet Hydrochloride. Profiles Drug Subst Excip Relat Methodol. 2017;42:1-90. doi: 10.1016/bs.podrm.2017.02.001. Epub 2017 Apr 3. PMID: 28431775. 7: Komaba H, Fukagawa M. Cinacalcet and Clinical Outcomes in Dialysis. Semin Dial. 2015 Nov-Dec;28(6):594-603. doi: 10.1111/sdi.12413. Epub 2015 Aug 12. PMID: 26265359. 8: Imanishi Y, Inaba M, Kawata T, Nishizawa Y. Cinacalcet in hyperfunctioning parathyroid diseases. Ther Apher Dial. 2009 Oct;13 Suppl 1:S7-S11. doi: 10.1111/j.1744-9987.2009.00768.x. PMID: 19765257. 9: Muñoz-Torres M, García-Martín A. Primary hyperparathyroidism. Med Clin (Barc). 2018 Mar 23;150(6):226-232. English, Spanish. doi: 10.1016/j.medcli.2017.07.020. Epub 2017 Oct 6. PMID: 28992983. 10: Sekercioglu N, Busse JW, Sekercioglu MF, Agarwal A, Shaikh S, Lopes LC, Mustafa RA, Guyatt GH, Thabane L. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2016 Jul;38(6):857-74. doi: 10.3109/0886022X.2016.1172468. Epub 2016 May 2. PMID: 27137817. 11: Eidman KE, Wetmore JB. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ? Semin Dial. 2018 Sep;31(5):440-444. doi: 10.1111/sdi.12734. Epub 2018 Jul 15. PMID: 30009474. 12: Leere JS, Karmisholt J, Robaczyk M, Lykkeboe S, Handberg A, Steinkohl E, Brøndum Frøkjær J, Vestergaard P. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2020 May;8(5):407-417. doi: 10.1016/S2213-8587(20)30063-2. PMID: 32333877. 13: Marcocci C, Cetani F. Update on the use of cinacalcet in the management of primary hyperparathyroidism. J Endocrinol Invest. 2012 Jan;35(1):90-5. doi: 10.3275/8112. Epub 2011 Nov 21. PMID: 22104762. 14: Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493. Drugs R D. 2003;4(6):349-51. doi: 10.2165/00126839-200304060-00003. PMID: 14584963. 15: Li X, Ding W, Zhang H. Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review. Front Endocrinol (Lausanne). 2023 Jul 19;14:1146955. doi: 10.3389/fendo.2023.1146955. PMID: 37538795; PMCID: PMC10395090. 16: Bernardor J, De Mul A, Bacchetta J, Schmitt CP. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients. Curr Osteoporos Rep. 2023 Apr;21(2):193-204. doi: 10.1007/s11914-023-00782-x. Epub 2023 Feb 27. PMID: 36848027. 17: Yousaf F, Charytan C. Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. Ren Fail. 2014 Feb;36(1):131-8. doi: 10.3109/0886022X.2013.832319. Epub 2013 Sep 24. PMID: 24060145. 18: Karohl C, Raggi P. Cinacalcet: will it play a role in reducing cardiovascular events? Future Cardiol. 2012 May;8(3):357-70. doi: 10.2217/fca.11.82. Epub 2012 Mar 15. PMID: 22420327. 19: Duntas LH, Stathatos N. Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects. Endocrine. 2011 Jun;39(3):199-204. doi: 10.1007/s12020-011-9452-7. Epub 2011 Mar 26. PMID: 21442382. 20: Cinacalcet (sensipar). Med Lett Drugs Ther. 2004 Sep 27;46(1192):80. PMID: 15452465.